News

There is always something new at ImmunoGenesis. Stay on top of the latest.

Press Releases

Key Publications

Development of IMGS-001, a novel anti–PD-L1/PD-L2 dual-specific, multifunctional antibody, to treat immune-excluded tumors.

C Gagliardi, A Salameh, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.

View poster
Preclinical characterization of IMGS-001, a dual-antagonist anti–PD-L1 and PD-L2 antibody with effector function, to treat patients resistant to immune checkpoint blockade.

A Salameh, C Gagliardi, P Blezinger, M Hemberger, C Schweizer, J Barlow, M Curran, F Pericle. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 8-12, 2022; Boston, MA.

View poster
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.

Burrack, AL, Spartz, EJ, Raynor, JF, Wang, I, Olson, M, Stromnes, IM. Cell Reports. 2019.

View publication
Genomic biomarkers in relation to PD-1 checkpoint blockade response.

Seiwert, TY, Cristescu, R, Kaufman, DR, et al. Journal of Clinical Oncology. 2018.

View publication
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Yearley, JH, Gibson, C, Yu, N, Moon, C, Murphy, E, McClanahan, T, et al. Clinical Cancer Research. 2017.

View publication
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Curran, MA, Montalvo, W, Yagita, H, Allison, JP. PNAS. 2010.

View publication

Upcoming events

There are no upcoming events scheduled at this time. Sign up to receive notices about upcoming events and press releases.